A nationwide shortage of BCG vaccines is leaving Kenyan newborns vulnerable to TB, a disease with high prevalence, health ...

[JONAH ONYANGO/STANDARD.] A nationwide shortage of Bacillus Calmette-Guerin (BCG) vaccines in the country leaves Kenyan newborns vulnerable to Tuberculosis (TB), a disease with a high prevalence ...

Health Non-Governmental Organisations Network (HENNET) has blamed low budgetary allocation for the recurring vaccine ...

With only seven members, iGEM Eindhoven forms a small but determined student team that aims to help shape the future of ...

JNJ's regulatory filing seeks the FDA's approval for TAR-200, a drug-device combination for treating certain bladder cancer ...

An experimental tuberculosis (TB) vaccine with a dual mission – self-destruction after inducing immunity – improved the design of the Bacillus Calmette-Guérin (BCG) immunotherapy, a vaccine also used ...

An FDA application for TAR-200 to treat BCG-unresponsive high-risk non-muscle-invasive bladder cancer is under real-time ...

Indeed, the BCG vaccine was invented whether the leprosy world asked for it or not; and it has not been necessary to consider the need for neonatal BCG vaccination to prevent leprosy, or to ...

The bacillus Calmette–Guérin (BCG) vaccine, initially developed to provide protection against TB, also protects against leprosy; and the magnitude of this effect varies. Previous meta-analyses ...

In vivo perturbations and single-cell RNA-seq reveal cell-type-specific STAT1-IFNg signaling in regulation of trained immunity in tissue-resident immune cells.

J&J acquired rights to TAR-200 when it bought privately-owned biotech Taris for an undisclosed sum in 2019, and has big sales ...